A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Brachial Plexus Block With EXPAREL for Postsurgical Analgesia in Subjects Undergoing Total Shoulder Arthroplasty or Rotator Cuff Repair

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Brachial Plexus Block With EXPAREL for Postsurgical Analgesia in Subjects Undergoing Total Shoulder Arthroplasty or Rotator Cuff Repair

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Apr 2018

At a glance

  • Drugs Bupivacaine (Primary)
  • Indications Postoperative pain
  • Focus Registrational; Therapeutic Use
  • Sponsors Pacira Pharmaceuticals
  • Most Recent Events

    • 09 Apr 2018 Results published in a Pacira Pharmaceuticals Media Release.
    • 09 Apr 2018 Pacira received U.S. Food and Drug Administration (FDA) approval for its supplemental new drug application for EXPAREL as a nerve block to produce regional analgesia, based on positive data from this phase 3 study of EXPAREL in brachial plexus block for shoulder surgeries, according to a Pacira Pharmaceuticals media release.
    • 15 Feb 2018 According to a Pacira Pharmaceuticals media release, The U.S. Food and Drug Administration's (FDA) Anesthetic and Analgesic Drug Products Advisory Committee did not reach an unanimous decision on the efficacy and safety of the use of EXPAREL, as a nerve block to produce regional analgesia. The FDA will consider this feedback, to review the company's sNDA seeking expansion of the EXPAREL label.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top